or Try an Advanced Search...

    Technical Analysis for RPRX - Royalty Pharma plc

    Grade Last Price % Change Price Change
    F 26.78 0.30% 0.08
    RPRX closed up 0.3 percent on Thursday, September 28, 2023, on 74 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical RPRX trend table...
    Date Alert Name Type % Chg
    Shooting Star Candlestick Bearish 0.00%
    1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Calm After Storm Range Contraction 0.00%
    Gapped Up Strength 0.30%
    Oversold Stochastic Weakness 0.30%
    1,2,3 Retracement Bearish Bearish Swing Setup 0.15%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.15%
    Calm After Storm Range Contraction 0.15%
    Up 3 Days in a Row Strength 0.15%
    Older End-of-Day Signals for RPRX ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    10 DMA Resistance about 10 hours ago
    Rose Above 10 DMA about 10 hours ago
    60 Minute Opening Range Breakout about 11 hours ago
    Up 1% about 11 hours ago
    Down 1% 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    RPRX Chart by TradingView
    Basic chart:

    Profile

    Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Pharmaceutical Pharmaceutical Products Drug Development HIV Biopharmaceutical Products

    Is RPRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Sep 27 Royalty Pharma: The Time Has Come
    Sep 21 Royalty Pharma appoints chief technology officer
    Sep 21 Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
    Sep 12 Are Royalty Pharma plc's (NASDAQ:RPRX) Mixed Financials Driving The Negative Sentiment?
    Sep 6 Royalty Pharma: We Continue To Like The Strategy And Sell-Off Is Overdone
    Sep 5 Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
    Sep 5 Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
    Sep 5 Royalty Pharma to Present at Upcoming Investor Conferences
    Aug 24 Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)
    Aug 24 Royalty Pharma and Ferring Pharmaceuticals enter $500M royalty agreement
    See more RPRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 43.6712
    52 Week Low 25.92
    Average Volume 2,042,913
    200-Day Moving Average 33.66
    50-Day Moving Average 29.44
    20-Day Moving Average 28.14
    10-Day Moving Average 27.04
    Average True Range 0.62
    RSI (14) 29.58
    ADX 31.55
    +DI 14.13
    -DI 33.02
    Chandelier Exit (Long, 3 ATRs) 29.00
    Chandelier Exit (Short, 3 ATRs) 27.79
    Upper Bollinger Bands 30.60
    Lower Bollinger Band 25.68
    Percent B (%b) 0.22
    BandWidth 17.50
    MACD Line -0.88
    MACD Signal Line -0.77
    MACD Histogram -0.1192
    Fundamentals Value
    Market Cap 9.8 Billion
    Num Shares 366 Million
    EPS -0.62
    Price-to-Earnings (P/E) Ratio -43.12
    Price-to-Sales 12.88
    Price-to-Book 5.94
    PEG Ratio -0.02
    Dividend 0.60
    Dividend Yield 2.24%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 27.43
    Resistance 3 (R3) 27.45 27.27 27.32
    Resistance 2 (R2) 27.27 27.10 27.25 27.28
    Resistance 1 (R1) 27.02 27.00 27.15 27.00 27.25
    Pivot Point 26.84 26.84 26.90 26.82 26.84
    Support 1 (S1) 26.59 26.67 26.72 26.57 26.31
    Support 2 (S2) 26.41 26.57 26.39 26.28
    Support 3 (S3) 26.16 26.41 26.24
    Support 4 (S4) 26.14